Australia reclassifies psychedelics to facilitate medical use, as advocates push for similar move in US
Australia’s Therapeutic Goods Administration (TGA) has reclassified two psychedelic substances to facilitate their use as medicines for certain mental health conditions, a move that some advocates say could serve as an example for the US.
Australia announced in February that starting July 1, authorized psychiatrists can prescribe drugs containing psilocybin, an active substance in “magic mushrooms,” and MDMA for treatment-resistant depression and post-traumatic stress disorder, respectively. Those are the only two conditions for which TGA has said there is “currently sufficient evidence for potential benefits.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.